IDH1 and glioma: In our series including a total of 35 glioma cases, here we provide evidence of high grade glioma case with positive IDH1 R132H mutation and MGMT promoter methylation that reached the long-term survival rate (over 36 month) when the PD-L1 expression status is negative, in comparison to its positive PD-L1 counterpart.